Sage Therapeutics (SAGE) Q3 2024 earnings summary

Executive summary

• ZURZUVAE, the first oral treatment for postpartum depression (PPD), drove revenue growth after its December 2023 U.S. launch, with collaboration revenue of $11 million in Q3 2024 and ~2,000 prescriptions shipped, a 40% sequential increase.

• Strategic reorganization and a 33% workforce reduction were implemented in October 2024 to strengthen the balance sheet, focus on ZURZUVAE for PPD, and prioritize pipeline development.

• Decision made to discontinue ZULRESSO commercial availability after December 31, 2024, and halt zuranolone development for MDD in the U.S.

• Pipeline setbacks include phase II LIGHTWAVE study in Alzheimer's disease not meeting primary endpoint and Biogen terminating the SAGE-324 collaboration, with Sage regaining full rights in February 2025.

• Net loss for the nine months ended September 30, 2024, was $304.9 million, with an accumulated deficit of $2.9 billion.

Financial highlights

• Q3 2024 total revenue was $22.1 million, with $11 million from collaboration revenue, representing 49% sequential growth and over 300% year-over-year increase.

• Net loss for Q3 2024 was $93.6 million, improved from $201.6 million in Q3 2023; net loss per share was $(1.53) vs. $(3.37) year-over-year.

• R&D expenses were $54.6 million and SG&A expenses were $53.2 million in Q3 2024, both down significantly year-over-year.

• Cash, cash equivalents, and marketable securities totaled $569 million as of September 30, 2024.

• Cost of revenues included a $3.6 million one-time write-off and impairment related to ZULRESSO discontinuation.

Outlook and guidance

• Operating expenses are expected to decrease in 2025 due to the reorganization, with continued investment in ZURZUVAE commercialization and pipeline assets.

• Existing cash and anticipated revenues are expected to support operations into 2026, with updated cash runway guidance forthcoming.

• No additional milestone payments from collaborations are anticipated for the remainder of 2024.

• Top-line data from the phase II DIMENSION study in Huntington's disease is expected late 2024.

• Goal to establish ZURZUVAE as the standard of care in PPD, expanding prescriber base and supporting repeat prescriptions.